Kuangli Bio-Tech Holdings Co., Ltd. (TPE:6431)
Taiwan · Delayed Price · Currency is TWD 26.60
+0.50 (1.92%)
At close: Feb 11, 2026
Kuangli Bio-Tech Holdings Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 387.37 | 381.3 | 293.37 | 342.16 | 332.63 | 86.97 | |
Revenue Growth (YoY) | 16.22% | 29.97% | -14.26% | 2.86% | 282.47% | -79.55% |
Cost of Revenue | 316.59 | 312.98 | 227.07 | 273.47 | 241.7 | 85.52 |
Gross Profit | 70.78 | 68.32 | 66.3 | 68.69 | 90.94 | 1.45 |
Selling, General & Admin | 178.52 | 174.15 | 149.91 | 125.19 | 91.53 | 50.29 |
Research & Development | 35.03 | 32.25 | 30.8 | 32.27 | 11.05 | 0.64 |
Operating Expenses | 221.75 | 213.38 | 179.96 | 157.71 | 98.33 | 50.17 |
Operating Income | -150.97 | -145.06 | -113.65 | -89.03 | -7.39 | -48.72 |
Interest Expense | -16.69 | -15.87 | -14.18 | -14.3 | -8.21 | -0.06 |
Interest & Investment Income | 5.97 | 1.71 | 5.13 | 2.54 | 0.46 | 1.45 |
Earnings From Equity Investments | - | - | - | - | 10.92 | 12.12 |
Currency Exchange Gain (Loss) | -7.21 | -1.19 | 1.44 | 10.95 | -0.99 | -6.07 |
Other Non Operating Income (Expenses) | -7.87 | 2.15 | 2.58 | 5.18 | 0.35 | 0.29 |
EBT Excluding Unusual Items | -176.77 | -158.26 | -118.68 | -84.66 | -4.86 | -40.99 |
Impairment of Goodwill | -26.01 | -26.01 | -9.17 | - | - | - |
Gain (Loss) on Sale of Assets | - | - | - | 0.15 | 64.27 | - |
Other Unusual Items | 0.01 | 1.87 | 4.18 | - | - | - |
Pretax Income | -202.77 | -182.4 | -123.67 | -84.51 | 59.41 | -40.99 |
Income Tax Expense | -9.42 | -9.6 | -19.51 | -13.78 | 4.78 | 0.9 |
Earnings From Continuing Operations | -193.36 | -172.79 | -104.16 | -70.73 | 54.64 | -41.89 |
Earnings From Discontinued Operations | - | - | - | -0.62 | -18.64 | -20.98 |
Net Income to Company | -193.36 | -172.79 | -104.16 | -71.35 | 36 | -62.87 |
Minority Interest in Earnings | - | - | - | 2.63 | -10.16 | - |
Net Income | -193.36 | -172.79 | -104.16 | -68.72 | 25.84 | -62.87 |
Net Income to Common | -193.36 | -172.79 | -104.16 | -68.72 | 25.84 | -62.87 |
Shares Outstanding (Basic) | 87 | 69 | 57 | 56 | 51 | 46 |
Shares Outstanding (Diluted) | 87 | 69 | 57 | 56 | 51 | 46 |
Shares Change (YoY) | 33.92% | 19.81% | 1.50% | 11.05% | 11.25% | - |
EPS (Basic) | -2.23 | -2.52 | -1.82 | -1.22 | 0.51 | -1.38 |
EPS (Diluted) | -2.23 | -2.52 | -1.82 | -1.22 | 0.51 | -1.38 |
Free Cash Flow | -165.26 | -77.68 | -87.58 | -43.46 | -18.67 | 0.27 |
Free Cash Flow Per Share | -1.91 | -1.13 | -1.53 | -0.77 | -0.37 | 0.01 |
Gross Margin | 18.27% | 17.92% | 22.60% | 20.08% | 27.34% | 1.67% |
Operating Margin | -38.97% | -38.04% | -38.74% | -26.02% | -2.22% | -56.02% |
Profit Margin | -49.91% | -45.32% | -35.50% | -20.09% | 7.77% | -72.29% |
Free Cash Flow Margin | -42.66% | -20.37% | -29.85% | -12.70% | -5.61% | 0.31% |
EBITDA | -98.24 | -94.08 | -75.7 | -58.24 | 11.42 | -45.34 |
EBITDA Margin | -25.36% | -24.67% | -25.80% | -17.02% | 3.43% | -52.13% |
D&A For EBITDA | 52.73 | 50.97 | 37.96 | 30.79 | 18.81 | 3.38 |
EBIT | -150.97 | -145.06 | -113.65 | -89.03 | -7.39 | -48.72 |
EBIT Margin | -38.97% | -38.04% | -38.74% | -26.02% | -2.22% | -56.02% |
Effective Tax Rate | - | - | - | - | 8.04% | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.